The inhaler is inspiratory flow-driven, which means that when the patient inhales through the mouthpiece, the substance will follow the inspired air into the airways. Patients take a daily maintenance dose of Fobumix Easyhaler and in addition take Fobumix Easyhaler as needed in response to symptoms. Patients should be advised to always have Fobumix Easyhaler available for rescue use. A randomised, double-blind study in 72 adult asthmatics (aged 18-70 years) was performed to evaluate efficacy of Fobumix Easyhaler compared to Symbicort Turbuhaler after a single dose. The enrolled patients had stable but less than optimally controlled asthma and their FEV1 was on average 1.92 L (62% of the predicted value). Two dose levels of formoterol were tested for both products, 9 mcg and 36 mcg. The difference in the primary parameter, average FEV1 over 12 hours, was negligible between the treatments at both doses. At the lower dose the difference between the treatments (Easyhaler-Turbuhaler) was 0.013 L (95% CI from -0.047 to 0.073 L) and at the higher dose -0.028 L (95% CI from -0.087 to 0.032 L).The study results confirmed equivalent bronchodilator efficacy between Fobumix Easyhaler and Symbicort Turbuhaler. Budesonide/formoterol maintenance and reliever therapy provided statistically significant and clinically meaningful reductions in severe exacerbations for all comparisons in all 5 studies. This included a comparison with budesonide/formoterol at a higher maintenance dose with terbutaline as reliever (study 735) and budesonide/formoterol at the same maintenance dose with either formoterol or terbutaline as reliever (study 734) (Table 2). In Study 735, lung function, symptom control, and reliever use were similar in all treatment groups. In Study 734, symptoms and reliever use were reduced and lung function improved, compared with both comparator treatments. In the 5 studies combined, patients receiving budesonide/formoterol maintenance and reliever therapy used, on average, no reliever inhalations on 57% of treatment days. There was no sign of development of tolerance over time.

During transfer from oral therapy to Fobumix Easyhaler a generally lower systemic steroid action will be experienced which may result in the appearance of allergic or arthritic symptoms such as rhinitis, eczema and muscle and joint pain. Specific treatment should be initiated for these conditions. A general insufficient glucocorticosteroid effect should be suspected if, in rare cases, symptoms such as tiredness, headache, nausea and vomiting should occur. In these cases a temporary increase in the dose of oral glucocorticosteroids is sometimes necessary. Fobumix Easyhaler contains approx. 4 mg of lactose per inhalation. This amount does not normally cause problems in lactose intolerant people. The excipient lactose contains small amounts of milk proteins, which may cause allergic reactions. In the division method, the factors of 80 are found by dividing 80 by different integer numbers. If the number divides 80 exactly and leaves the remainder 0, then those integers are the factors of 80. Now, let us discuss how to find the factors of 80 by division method. Data on approximately 2000 exposed pregnancies indicate no increased teratogenic risk associated with the use of inhaled budesonide. In animal studies glucocorticosteroids have been shown to induce malformations (see section 5.3). This is not likely to be relevant for humans given recommended doses.

Video Lesson on Prime Factors

The dose should be titrated to the lowest dose at which effective control of symptoms is maintained. Patients should be regularly reassessed by their prescriber/health care provider so that the dosage of Fobumix Easyhaler remains optimal. When long-term control of symptoms is maintained with the lowest recommended dosage, then the next step could include a test of inhaled corticosteroid alone.

Potential effects on bone density should be considered, particularly in patients on high doses for prolonged periods that have coexisting risk factors for osteoporosis. Long-term studies with inhaled budesonide in children at mean daily doses of 400 micrograms (metered dose) or in adults at daily doses of 800 micrograms (metered dose) have not shown any significant effects on bone mineral density. No information regarding the effect at higher doses is available.

Reduce 80/4 to lowest terms

As with other inhalation therapy, paradoxical bronchospasm may occur, with an immediate increase in wheezing and shortness of breath after dosing. If the patient experiences paradoxical bronchospasm Fobumix Easyhaler should be discontinued immediately, the patient should be assessed and an alternative therapy instituted, if necessary. Paradoxical bronchospasm responds to a rapid-acting inhaled bronchodilator and should be treated straightaway (see section 4.8). There are no special dosing requirements for elderly patients. There are no data available for use of Fobumix Easyhaler in patients with hepatic or renal impairment. As budesonide and formoterol are primarily eliminated via hepatic metabolism, an increased exposure can be expected in patients with severe liver cirrhosis. Here we will show you step-by-step with detailed explanation how to calculate 80 divided by 4 using long division. Concomitant treatment with quinidine, disopyramide, procainamide, phenothiazines, antihistamines (terfenadine), and tricyclic antidepressants can prolong the QTc-interval and increase the risk of ventricular arrhythmias. Subtract the result in the previous step from the first digit of the dividend (8 - 8 = 0) and write the answer below.

Proper fraction button and Improper fraction button work as pair. When you choose the one the other is switched off. Concomitant treatment with itraconazole, ritonavir or other potent CYP3A inhibitors should be avoided (see section 4.5). If this is not possible the time interval between administration of the interacting drugs should be as long as possible. In patients using potent CYP3A inhibitors, maintenance and reliever therapy approach is not recommended. Animal studies have also identified an involvement of excess prenatal glucocorticoids in increased risks for intrauterine growth retardation, adult cardiovascular disease and permanent changes in glucocorticoid receptor density, neurotransmitter turnover and behaviour at exposures below the teratogenic dose range.Patients should not be initiated on Fobumix Easyhaler during an exacerbation, or if they have significantly worsening or acutely deteriorating asthma. The benefits of inhaled budesonide therapy would normally minimise the need for oral steroids, but patients transferring from oral steroids may remain at risk of impaired adrenal reserve for a considerable time. Recovery may take a considerable amount of time after cessation of oral steroid therapy and hence oral steroid-dependent patients transferred to inhaled budesonide may remain at risk from impaired adrenal function for some considerable time. In such circumstances HPA axis function should be monitored regularly.

There is an elevated risk of arrhythmias in patients receiving concomitant anaesthesia with halogenated hydrocarbons. To clean the mouthpiece with a dry cloth at regular intervals. Water should never be used for cleaning because the powder is sensitive to moisture. Concomitant use of other beta-adrenergic drugs or anticholinergic drugs can have a potentially additive bronchodilating effect.

Fun

Proper fraction button is used to change a number of the form of 9/5 to the form of 1 4/5. A proper fraction is a fraction where the numerator (top number) is less than the denominator (bottom number). If patients find the treatment ineffective, or exceed the highest recommended dose of Fobumix Easyhaler, medical attention must be sought (see section 4.2). Sudden and progressive deterioration in control of asthma is potentially life threatening and the patient should undergo urgent medical assessment. In this situation, consideration should be given to the need for increased therapy with corticosteroids, e.g. a course of oral corticosteroids, or antibiotic treatment if an infection is present.